BioSpace News Archive

MyMD Pharmaceuticals, Inc. is presenting data today at the 2022 British Society for Immunology (BSI) Congress in Liverpool, England.

Bluestar Genomics, Inc. announced the initiation of the New Onset Diabetes Management for Earlier Detection (NODMED) trial, one of the largest clinical studies in pancreatic cancer to date.

Verge Genomics announced today that it appointed Diego Cadavid, M.D., as its first Chief Medical Officer.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that SELLAS’ highly selective CDK9 inhibitor, GFH009, will be evaluated in pediatric solid tumors and leukemia models through the National Cancer Institute (NCI) Pediatric Preclinical in Vivo Testing (PIVOT) Program.

ChroniSense Medical Ltd. took a step towards its vision of transforming chronic care management with Polso™, the company’s Remote Patient Monitoring (RPM) solution, achieving 510(k) clearance from the U.S. Food and Drug Administration (FDA).

According to Nova one advisor, the global Age-related Macular Degeneration market size was estimated at USD 10.40 billion in 2022 and is projected to hit around USD 18.29 billion by 2030, growing at a CAGR of 6.70% during the forecast period 2022 to 2030.

According to Nova one advisor, the global AI In Cancer Diagnostics market size is expected to hit around USD 1.2 billion by 2030 from valued at USD 93.9 million in 2021 and growing at a CAGR of 28.9% from 2022 to 2030.

According to Nova one advisor, the global Drug Discovery Services market size is expected to hit around USD 34.2 billion by 2030 from valued at USD 16.9 billion in 2021 and growing at a CAGR of 14.9% from 2022 to 2030.

AXIM Biotechnologies, Inc, an international healthcare diagnostic solutions development company, announced that its ophthalmic diagnostic tear based solutions were featured in leading scientific media environments including Eyes On 2023 and Ophthalmology Times.

Molecular Assemblies, Inc., a pioneer in the field of enzymatic DNA synthesis, announced the appointment of Mark Nibbe as Vice President, Operations.